Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VIVUS Inc (NASDAQ:VVUS)

1.10
Delayed Data
As of 3:59pm ET
 -0.02 / -1.79%
Today’s Change
0.93
Today|||52-Week Range
1.47
-4.35%
Year-to-Date
Achaogen's Plazomicin Gets Breakthrough Therapy Designation
11:40am / Zacks.com - Paid Partner Content
Merck Presents Phase II Data on Chronic Cough Candidate
May 23 / Zacks.com - Paid Partner Content
Theravance/Mylan Presents Phase III Data on COPD Candidate
11:19am / Zacks.com - Paid Partner Content
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
May 23 / Zacks.com - Paid Partner Content
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
11:19am / Zacks.com - Paid Partner Content
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
May 23 / Zacks.com - Paid Partner Content
Ultragenyx Receives Priority Review for rhGUS from FDA
10:01am / Zacks.com - Paid Partner Content
Catalyst Pharmaceuticals Focuses on Development of Firdapse
May 23 / Zacks.com - Paid Partner Content
BioLineRx Makes Regulatory Submission for Trial of BL-8040
May 23 / Zacks.com - Paid Partner Content
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
May 23 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close1.12
Today’s open1.12
Day’s range1.05 - 1.13
Volume1,187,375
Average volume (3 months)611,506
Market cap$118.4M
Dividend yield--
Data as of 3:59pm ET, 05/24/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-277.27%
Earnings growth (next 5 years)+0.84%
Revenue growth (last year)+30.21%
P/E ratio3.3
Price/Sales0.97
Price/Book6.46

Competitors

 Today’s
change
Today’s
% change
ORMPOramed Pharmaceutica...-0.19-2.21%
VTLVital Therapies Inc0.000.00%
GEMPGemphire Therapeutic...-0.03-0.30%
CPIXCumberland Pharmaceu...+0.01+0.14%
Data as of 3:59pm ET, 05/24/2017

Financials

Next reporting dateAugust 8, 2017
EPS forecast (this quarter)-$0.13
Annual revenue (last year)$124.3M
Annual profit (last year)$23.3M
Net profit margin18.75%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Director
Seth H. Z. Fischer
Chief Financial &
Accounting Officer
Mark K. Oki
Corporate headquarters
Campbell, California

Forecasts